First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial
Source: View publication →
A novel first-line triplet regimen combining the HER2-targeted antibody-drug conjugate disitamab vedotin, the PD-1 inhibitor tislelizumab, and S-1 demonstrated a high objective response rate of 89.5% and a median overall survival of 31.9 months in patients with HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma.
Key Findings
Study Design
Study Limitations
Clinical Significance
This phase II trial provides robust preliminary evidence that replacing traditional anti-HER2 monoclonal antibodies and conventional chemotherapy with an MMAE-based antibody-drug conjugate (disitamab vedotin) in combination with immunotherapy (tislelizumab) and S-1 produces profound and durable responses in HER2-overexpressing gastric and gastroesophageal junction (G/GEJ) adenocarcinomas. Most notably, substantial activity was preserved in patients with PD-L1 CPS <1 and those with HER2 IHC 2+/ISH- tumors, subgroups that historically derive limited benefit from standard trastuzumab/pembrolizumab paradigms. These compelling data support advancing this ADC-immuno-chemotherapy triplet into randomized phase III testing as a potential new first-line standard.
Historical Context
Historically, the pivotal ToGA trial (2010) established trastuzumab plus fluoropyrimidine- and platinum-based chemotherapy as the standard first-line treatment for HER2-positive advanced gastric cancer. Recently, the KEYNOTE-811 trial demonstrated that adding pembrolizumab to this backbone improved outcomes, leading to regulatory approvals, but the benefit was largely restricted to patients with strict HER2 positivity and PD-L1 CPS ≥1. Disitamab vedotin is a novel HER2-targeted ADC possessing a cleavable linker and a potent MMAE payload that elicits a 'bystander effect', destroying adjacent tumor cells regardless of their HER2 status. Driven by preclinical evidence showing that ADCs induce immunogenic cell death and synergize with PD-1 blockade, this trial successfully brought an ADC into the first-line setting, moving beyond the traditional ToGA paradigm.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of an antibody-drug conjugate like disitamab vedotin differ from traditional monoclonal antibodies like trastuzumab in the treatment of HER2-overexpressing gastric cancer?
Key Response
Trastuzumab primarily inhibits HER2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC). Disitamab vedotin utilizes a HER2-directed antibody to deliver a cytotoxic payload (MMAE) directly into the tumor cell, allowing for targeted cytotoxicity even in tumors with heterogeneous HER2 expression via the bystander effect.
Given the standard of care established by the KEYNOTE-811 trial for HER2-positive advanced gastric cancer, how does the regimen in this Phase II trial conceptually modify the current standard first-line treatment?
Key Response
The current standard is trastuzumab, fluoropyrimidine and platinum chemotherapy, plus pembrolizumab. This trial substitutes the standard monoclonal antibody with an ADC (disitamab vedotin), drops the platinum agent, uses S-1 instead of 5-FU or capecitabine, and swaps pembrolizumab for tislelizumab, attempting to maximize efficacy while potentially altering the toxicity profile.
Disitamab vedotin uses monomethyl auristatin E (MMAE) as its payload. What specific overlapping toxicities might you anticipate when combining an MMAE-based ADC with a fluoropyrimidine (S-1) and an immune checkpoint inhibitor, and how might this impact dose intensity?
Key Response
MMAE is known for causing peripheral neuropathy and neutropenia. S-1 can also cause myelosuppression and gastrointestinal toxicities. Combining an ADC that causes neutropenia with standard chemotherapy can lead to significant additive myelosuppression, potentially requiring dose interruptions that compromise the dose intensity and long-term efficacy.
While an ORR of 89.5% and median OS of 31.9 months are historically unprecedented in this population, why must we be cautious about integrating single-arm Phase II survival data into routine practice for advanced gastric cancer?
Key Response
Single-arm trials are subject to significant selection bias, often enrolling fitter patients with lower disease burden. Furthermore, survival endpoints in Phase II trials can be heavily confounded by subsequent lines of therapy and lack a concurrent control arm (like the KEYNOTE-811 control arm) to account for stage migration and improvements in supportive care, making randomized Phase III data essential.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
How does the lack of a randomized control arm in this Phase II trial impact the ability to delineate the independent contribution of the PD-1 inhibitor (tislelizumab) versus the HER2-ADC (disitamab vedotin), and what trial design would best address this?
Key Response
In a single-arm triplet study, it is impossible to determine whether the synergistic effect is driven by the ADC plus chemo, the PD-1 plus chemo, or the full triplet. A factorial design or a multi-arm randomized trial is required to parse out the relative contributions and justify the added toxicity and cost of the triplet regimen.
As a reviewer evaluating this manuscript, what critical baseline demographic and molecular data, such as PD-L1 CPS score and HER2 immunohistochemistry distribution, would you require the authors to report to assess the true generalizability of this 89.5% ORR?
Key Response
Gastric cancer response to PD-1 inhibitors is highly dependent on PD-L1 CPS, and ADC efficacy can vary by HER2 expression levels. A tough reviewer would flag that if the cohort is disproportionately skewed toward CPS greater than 10 or exclusively IHC 3+ patients, the remarkable ORR might just reflect a highly selected, biologically favorable subgroup rather than a broad regimen effect.
The NCCN and ESMO guidelines currently recommend trastuzumab, chemotherapy, and pembrolizumab for HER2-positive first-line gastric cancer based on KEYNOTE-811. What level of evidence does this study provide, and what threshold of data is required before guidelines would adopt this triplet regimen?
Key Response
This single-arm Phase II trial provides Level 3 (or Category 2B) evidence, which is insufficient to supplant a Category 1 recommendation. For guidelines to update the standard of care to include an ADC in the first-line setting, a randomized Phase III trial demonstrating superiority or non-inferiority in OS and PFS compared to the KEYNOTE-811 standard regimen is strictly required.
Clinical Landscape
Noteworthy Related Trials
ToGA Trial
Tested
Trastuzumab + chemotherapy
Population
Patients with HER2-positive advanced gastric or gastroesophageal junction cancer
Comparator
Chemotherapy alone
Endpoint
Overall survival
DESTINY-Gastric01
Tested
Trastuzumab deruxtecan (T-DXd)
Population
Patients with HER2-positive advanced gastric cancer progressed on at least two prior regimens
Comparator
Physician's choice of chemotherapy (irinotecan or paclitaxel)
Endpoint
Objective response rate
KEYNOTE-811
Tested
Pembrolizumab + trastuzumab + chemotherapy
Population
Patients with previously untreated, HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma
Comparator
Placebo + trastuzumab + chemotherapy
Endpoint
Progression-free survival and overall survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis